FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384342022> ?p ?o ?g. }

• W4384342022 abstract "<p>Supplementary Figure 3: PPP1CB-ALK fusion is oncogenic and sensitive to targeted therapy. A. Immunoblot analysis of ALK downstream signaling proteins in cortical mNSC (CTX#6) and brainstem mNSC (BS#3) expressing PPP1CB-ALK. Cells were treated for 4 hours with ceritinib and lorlatinib at the indicated concentrations.B. Left panel: Soft agar colony-forming assay using stable mNSC PPP1CB-ALK demonstrated colony formation with dose-dependent inhibition by ceritinib. mNSC KRAS did not respond to ceritinib validating the drug specificity. Right panel: Quantification of colony formation under targeted drug inhibition using CellProfiler. Values represent colony counts relative to the untreated group ± s.d. The mean of three independent replicates is shown. Significance between treatments determined by the Mann-Whitney test. *P < 0.05, **P < 0.01.C. Cell viability of ceritinib-treated PPP1CB-ALK NIH-3T3 relative to eGFP-positive cells by CellTiterGlo.D. Relative viability of the ALK wild-type GBM line (BT164) and BT1857 lorlatinib-treated cells versus DMSO control.E. Relative viability of BT164 and BT1857 ceritinib-treated cells versus DMSO control.F. Relative viability of BT164 and BT1857 cells treated with an EGFR tyrosine kinase inhibitor neratinib.G. Pharmacodynamic analysis of NIH 3T3-PPP1CB-ALK s.c. tumors treated with vehicle or ceritinib at 30mg/kg for 5 days. Representative H&E stain, ALK, pSTAT3, pAKT S473 and Ki-67 IHC.H. Quantification of Ki-67-positive cells in vehicle and ceritinib-treated tumors using CellProfiler software. Error bars show standard error of the mean. *P < 0.05.I. Quantification of pSTAT3-positive cells in vehicle and ceritinib-treated tumors using CellProfiler software. Error bars show standard error of the mean. *P < 0.05.J. Tumor growth following subcutaneous implantation of PPP1CB-ALK and eGFP-expressing fibroblasts.K. Kaplan-Meier survival curves of SCID mice injected subcutaneously with mNSC CTX-PPP1CB-ALK (red, n = 5) or mNSC CTX-eGFP (black, n = 4) and treated with ceritinib at 30mg/kg/d for 15 days. Mice were euthanized at endpoint (tumor volume of 2000mm3). The grey area represents the treatment period.L. Vehicle or ceritinib-treated mouse weights at start and end of treatment.</p>" @default.
• W4384342022 created "2023-07-15" @default.
• W4384342022 creator A5001355914 @default.
• W4384342022 creator A5004402830 @default.
• W4384342022 creator A5007890638 @default.
• W4384342022 creator A5010270402 @default.
• W4384342022 creator A5012992077 @default.
• W4384342022 creator A5021656597 @default.
• W4384342022 creator A5024876144 @default.
• W4384342022 creator A5026339662 @default.
• W4384342022 creator A5027292735 @default.
• W4384342022 creator A5027575883 @default.
• W4384342022 creator A5032098479 @default.
• W4384342022 creator A5034760960 @default.
• W4384342022 creator A5036617904 @default.
• W4384342022 creator A5036844254 @default.
• W4384342022 creator A5037228057 @default.
• W4384342022 creator A5038992066 @default.
• W4384342022 creator A5039022911 @default.
• W4384342022 creator A5041980697 @default.
• W4384342022 creator A5043153075 @default.
• W4384342022 creator A5044684517 @default.
• W4384342022 creator A5044869256 @default.
• W4384342022 creator A5045184874 @default.
• W4384342022 creator A5046557285 @default.
• W4384342022 creator A5047888321 @default.
• W4384342022 creator A5049957915 @default.
• W4384342022 creator A5054071842 @default.
• W4384342022 creator A5056099258 @default.
• W4384342022 creator A5056581996 @default.
• W4384342022 creator A5059965175 @default.
• W4384342022 creator A5060208068 @default.
• W4384342022 creator A5060358208 @default.
• W4384342022 creator A5061990450 @default.
• W4384342022 creator A5063515630 @default.
• W4384342022 creator A5063572228 @default.
• W4384342022 creator A5065891037 @default.
• W4384342022 creator A5066878975 @default.
• W4384342022 creator A5068793931 @default.
• W4384342022 creator A5077011745 @default.
• W4384342022 creator A5079681291 @default.
• W4384342022 creator A5084589096 @default.
• W4384342022 creator A5085626192 @default.
• W4384342022 creator A5087534739 @default.
• W4384342022 creator A5088254403 @default.
• W4384342022 creator A5090417424 @default.
• W4384342022 creator A5090423495 @default.
• W4384342022 creator A5091809423 @default.
• W4384342022 date "2023-07-14" @default.
• W4384342022 modified "2023-10-15" @default.
• W4384342022 title "Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma" @default.
• W4384342022 doi "https://doi.org/10.1158/1078-0432.23683911.v1" @default.
• W4384342022 hasPublicationYear "2023" @default.
• W4384342022 type Work @default.
• W4384342022 citedByCount "0" @default.
• W4384342022 crossrefType "posted-content" @default.
• W4384342022 hasAuthorship W4384342022A5001355914 @default.
• W4384342022 hasAuthorship W4384342022A5004402830 @default.
• W4384342022 hasAuthorship W4384342022A5007890638 @default.
• W4384342022 hasAuthorship W4384342022A5010270402 @default.
• W4384342022 hasAuthorship W4384342022A5012992077 @default.
• W4384342022 hasAuthorship W4384342022A5021656597 @default.
• W4384342022 hasAuthorship W4384342022A5024876144 @default.
• W4384342022 hasAuthorship W4384342022A5026339662 @default.
• W4384342022 hasAuthorship W4384342022A5027292735 @default.
• W4384342022 hasAuthorship W4384342022A5027575883 @default.
• W4384342022 hasAuthorship W4384342022A5032098479 @default.
• W4384342022 hasAuthorship W4384342022A5034760960 @default.
• W4384342022 hasAuthorship W4384342022A5036617904 @default.
• W4384342022 hasAuthorship W4384342022A5036844254 @default.
• W4384342022 hasAuthorship W4384342022A5037228057 @default.
• W4384342022 hasAuthorship W4384342022A5038992066 @default.
• W4384342022 hasAuthorship W4384342022A5039022911 @default.
• W4384342022 hasAuthorship W4384342022A5041980697 @default.
• W4384342022 hasAuthorship W4384342022A5043153075 @default.
• W4384342022 hasAuthorship W4384342022A5044684517 @default.
• W4384342022 hasAuthorship W4384342022A5044869256 @default.
• W4384342022 hasAuthorship W4384342022A5045184874 @default.
• W4384342022 hasAuthorship W4384342022A5046557285 @default.
• W4384342022 hasAuthorship W4384342022A5047888321 @default.
• W4384342022 hasAuthorship W4384342022A5049957915 @default.
• W4384342022 hasAuthorship W4384342022A5054071842 @default.
• W4384342022 hasAuthorship W4384342022A5056099258 @default.
• W4384342022 hasAuthorship W4384342022A5056581996 @default.
• W4384342022 hasAuthorship W4384342022A5059965175 @default.
• W4384342022 hasAuthorship W4384342022A5060208068 @default.
• W4384342022 hasAuthorship W4384342022A5060358208 @default.
• W4384342022 hasAuthorship W4384342022A5061990450 @default.
• W4384342022 hasAuthorship W4384342022A5063515630 @default.
• W4384342022 hasAuthorship W4384342022A5063572228 @default.
• W4384342022 hasAuthorship W4384342022A5065891037 @default.
• W4384342022 hasAuthorship W4384342022A5066878975 @default.
• W4384342022 hasAuthorship W4384342022A5068793931 @default.
• W4384342022 hasAuthorship W4384342022A5077011745 @default.
• W4384342022 hasAuthorship W4384342022A5079681291 @default.
• W4384342022 hasAuthorship W4384342022A5084589096 @default.
• W4384342022 hasAuthorship W4384342022A5085626192 @default.
• W4384342022 hasAuthorship W4384342022A5087534739 @default.
• W4384342022 hasAuthorship W4384342022A5088254403 @default.
• W4384342022 hasAuthorship W4384342022A5090417424 @default.

• next